SecSonar.com

Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Zenas BioPharma, Inc. (ZBIO) is a Biotechnology company based in US with a market capitalization of $829.2M. Revenue grew 100.0% year-over-year and free cash flow was negative at -$172.4M. This page tracks ZBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 130 employees · IPO Sep 13, 2024

Valuation

Valuation & price

$18.34 · as of May 17, 2026 · -57.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.42

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$43.17$26.48$9.79Jul 25Dec 25Jul 26Jul 7, 25$9.79Jul 9, 25$10.49Jul 11, 25$11.18Jul 15, 25$12.35Jul 17, 25$13.18Jul 21, 25$14.29Jul 23, 25$15.62Jul 25, 25$15.66Jul 29, 25$16.05Jul 31, 25$15.71Aug 4, 25$16.81Aug 6, 25$15.70Aug 11, 25$14.91Aug 13, 25$16.71Aug 15, 25$16.82Aug 19, 25$15.85Aug 21, 25$16.93Aug 25, 25$16.56Aug 27, 25$16.71Aug 29, 25$16.00Sep 3, 25$17.14Sep 5, 25$20.51Sep 9, 25$21.84Sep 11, 25$20.17Sep 16, 25$18.24Sep 18, 25$19.46Sep 22, 25$18.95Sep 24, 25$20.28Sep 26, 25$20.09Sep 30, 25$22.20Oct 2, 25$20.95Oct 6, 25$23.03Oct 8, 25$25.90Oct 10, 25$26.59Oct 14, 25$25.85Oct 16, 25$24.21Oct 21, 25$26.03Oct 23, 25$25.01Oct 27, 25$31.80Oct 29, 25$28.01Oct 31, 25$31.25Nov 4, 25$29.95Nov 6, 25$32.46Nov 10, 25$32.47Nov 12, 25$35.80Nov 14, 25$35.00Nov 18, 25$36.21Nov 20, 25$34.84Nov 25, 25$39.86Nov 28, 25$38.83Dec 2, 25$34.50Dec 4, 25$38.11Dec 8, 25$39.37Dec 10, 25$39.10Dec 12, 25$40.59Dec 16, 25$36.89Dec 18, 25$35.07Dec 22, 25$42.33Dec 24, 25$43.17Dec 29, 25$39.05Jan 2, 26$34.50Jan 6, 26$15.20Jan 8, 26$16.41Jan 12, 26$19.78Jan 14, 26$22.56Jan 16, 26$20.16Jan 21, 26$19.59Jan 23, 26$20.09Jan 27, 26$20.07Jan 29, 26$20.88Feb 2, 26$18.15Feb 4, 26$20.66Feb 9, 26$22.48Feb 11, 26$23.27Feb 13, 26$26.40Feb 18, 26$26.68Feb 20, 26$25.88Feb 24, 26$26.07Feb 26, 26$26.36Mar 2, 26$25.56Mar 4, 26$25.82Mar 6, 26$25.28Mar 10, 26$25.92Mar 12, 26$24.50Mar 17, 26$23.48Mar 19, 26$23.37Mar 23, 26$20.63Mar 25, 26$22.19Mar 27, 26$18.21Mar 31, 26$19.55Apr 2, 26$21.46Apr 7, 26$22.48Apr 9, 26$21.28Apr 13, 26$21.04Apr 15, 26$21.05Apr 17, 26$21.82Apr 22, 26$20.07Apr 24, 26$18.19Apr 28, 26$18.01Apr 30, 26$19.32May 4, 26$21.56May 6, 26$20.83May 8, 26$19.64May 12, 26$19.16May 14, 26$18.90May 18, 26$16.91May 20, 26$19.56May 22, 26$18.97May 28, 26$18.56Jun 1, 26$18.17Jun 3, 26$17.40Jun 5, 26$17.47Jun 9, 26$18.42Jun 11, 26$17.76Jun 15, 26$18.71Jun 17, 26$18.58Jun 22, 26$20.80Jun 24, 26$21.80Jun 26, 26$25.87Jul 2, 26$27.23
$9.7952-week range$43.17
Loading valuation history…

Fundamentals

Key fundamentals

$829.2M

Market cap

100.0%

Revenue growth (YoY)

100.0%

Gross margin

-$172.4M

Free cash flow (USD)

-$263.2M

Net debt

Net cash position

7.0%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2022 → 2025

FY 2022$0.00FY 2023$50.0MFY 2024$5.0MFY 2025$10.0M
$0$10M

Free cash flow by year

2022 → 2025

FY 2022$-67.8MFY 2023$-30.5MFY 2024$-119.8MFY 2025$-172.4M
-$67.9M-$172.4M

Gross margin by year

2023 → 2025

FY 2023100.0%FY 2024-2682.8%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

2

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider buyInsider Buy $1.0MMOULDER LEON O JR · Director, Chief Executive Officer · $1MMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • Insider buyInsider Buy $1.1MMOULDER LEON O JR · Director, Chief Executive Officer · $1.1MApr 29, 2026Filing
  • Insider buyInsider Buy $70KLu Hongbo · Director · $70.2KApr 2, 2026Filing
  • Insider buyInsider Buy $3.0MFairmount Funds Management LLC · Director · $3MApr 1, 2026Filing

Questions

Frequently asked questions

What is Zenas BioPharma, Inc.'s market cap?

Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $829.2M.

What is ZBIO's P/E ratio?

A meaningful P/E ratio is not available for ZBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ZBIO's price-to-book (P/B) ratio?

ZBIO trades at 3.42 times book value per share.

Are insiders buying ZBIO stock?

Yes — SEC Form 4 filings show 2 open-market insider buys and 0 sells at Zenas BioPharma, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

ETON

Eton Pharmaceuticals, Inc.

$834.6M

TBPH

Theravance Biopharma, Inc.

$835.7M

GERN

Geron Corporation

$805.1M

PHAT

Phathom Pharmaceuticals, Inc.

$788.3M

XNCR

Xencor, Inc.

$885.3M

JANX

Janux Therapeutics, Inc.

$894.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.